Bio-Thera Solutions, Ltd.
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
1
Ending by 2030
Apr 2027
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Oct 19, 2027The maintenance fee for Compounds and Methods for the Treatment of Egfr Positive Diseases (US 9,314,536) comes due Oct 19, 2027. Unpaid by Apr 19, 2028, it lapses early.
Recent changes
- 3 of the patents on this record were granted since Aug 17, 2026
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 7,498,410 | Bifunctional Variants of Recombinant Tissue-Type Plasminogen Activator with Platelet Aggregation Inhibitory Activity In force · High confidence | In force | High confidence | |
| US 8,877,706 | Maytansinoid Derivatives In force · High confidence | In force | High confidence | |
| US 8,889,855 | Preparation of Maytansinoid Esters In force · High confidence | In force | High confidence | |
| US 9,314,536 | Compounds and Methods for the Treatment of Egfr Positive Diseases In force · High confidence | In force | High confidence | |
| US 9,345,786 | Maytansinoid Derivatives In force · High confidence | In force | High confidence | |
| US 9,737,616 | Compounds and Methods for the Treatment of Erb B2/NEU Positive Diseases In force · Medium confidence | In force | Medium confidence | |
| US 9,567,403 | Bispecific Antibodies Which Bind Egfr and VEGF In force · High confidence | In force | High confidence | |
| US 11,505,609 | Recombinant Antibody Having Unique Glycan Profile Produced by Cho Host Cell with Edited Genome and Preparation Method Thereof In force · High confidence | In force | High confidence | |
| US 11,192,954 | Compounds and methods for the treatment of TROP2 positive diseases In force · From the USPTO record | In force | From the USPTO record | |
| US 12,679,895 | Recombinant Antibody Having Unique Glycan Profile Produced by Cho Host Cell with Edited Genome and Preparation Method Thereof In force · High confidence | In force | High confidence |
Also on record, not counted in the 15: 1 ended at full term. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
16 pending · 2 abandoned · 10 no status recorded